VistaGen Gets $36M Through Sale of Majority Stake | GenomeWeb

NEW YORK (GenomeWeb News) – VistaGen Therapeutics, a developer of bioassays for drug rescue projects, has signed a strategic financing agreement that will bring in proceeds of $36 million.

Under the agreement, VistaGen will provide 72 million shares of its restricted common stock at $.50 per share to the European subsidiary of Bergamo Acquisition Corp. The deal will provide Bergamo with a majority stake in VistaGen, which currently has around 20 million shares outstanding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.